<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>26(1)</volume><submitter>Hamblin R</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>The optimal management approach for presumed non-functioning pituitary microadenomas (microNFPAs) remains unclear. Our aim was to capture current UK practice and identify changes with time.&lt;h4>Methods&lt;/h4>Two online surveys investigating clinicians' approaches were performed in 2009-2010 and 2021-2022 (advertised through Society for Endocrinology UK).&lt;h4>Results&lt;/h4>150 and 214 clinicians participated in the 2021 and 2009 survey, respectively (response rates 31.2% and 35.4%, respectively). At baseline, 2021 survey respondents were more likely to measure IGF-1 (96.0% vs 74.1%, p &lt; 0.001) and morning cortisol (87.9% vs 62.6%, p &lt; 0.001), and less likely GH (26.2% vs 42.6% p = 0.002), 24 h urine free cortisol (3.4% vs 23.2%, p &lt; 0.0001) or dynamically assess adrenal reserve (1</pubmed_abstract><journal>Pituitary</journal><pagination>94-104</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9908737</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>UK practice on incidentally detected non-functioning pituitary microadenomas: analysis of two national surveys during a 12-year interval.</pubmed_title><pmcid>PMC9908737</pmcid><pubmed_authors>Fountas A</pubmed_authors><pubmed_authors>Hamblin R</pubmed_authors><pubmed_authors>Karavitaki N</pubmed_authors><pubmed_authors>Levy M</pubmed_authors></additional><is_claimable>false</is_claimable><name>UK practice on incidentally detected non-functioning pituitary microadenomas: analysis of two national surveys during a 12-year interval.</name><description>&lt;h4>Purpose&lt;/h4>The optimal management approach for presumed non-functioning pituitary microadenomas (microNFPAs) remains unclear. Our aim was to capture current UK practice and identify changes with time.&lt;h4>Methods&lt;/h4>Two online surveys investigating clinicians' approaches were performed in 2009-2010 and 2021-2022 (advertised through Society for Endocrinology UK).&lt;h4>Results&lt;/h4>150 and 214 clinicians participated in the 2021 and 2009 survey, respectively (response rates 31.2% and 35.4%, respectively). At baseline, 2021 survey respondents were more likely to measure IGF-1 (96.0% vs 74.1%, p &lt; 0.001) and morning cortisol (87.9% vs 62.6%, p &lt; 0.001), and less likely GH (26.2% vs 42.6% p = 0.002), 24 h urine free cortisol (3.4% vs 23.2%, p &lt; 0.0001) or dynamically assess adrenal reserve (1</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-21T22:45:10.485Z</modification><creation>2025-04-05T18:52:59.888Z</creation></dates><accession>S-EPMC9908737</accession><cross_references><pubmed>36434293</pubmed><doi>10.1007/s11102-022-01290-4</doi></cross_references></HashMap>